RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(38): 1917-1921
DOI: 10.1055/s-0028-1085577
DOI: 10.1055/s-0028-1085577
Übersicht | Review article
Gastroenterologie© Georg Thieme Verlag KG Stuttgart · New York
Nutzen und Risiken der Immunsuppression bei chronisch entzündlichen Darmerkrankungen
Benefits and risks of immunosuppression in inflammatory bowel diseaseWeitere Informationen
Publikationsverlauf
eingereicht: 31.3.2008
akzeptiert: 30.7.2008
Publikationsdatum:
10. September 2008 (online)

Schlüsselwörter
Immunsuppression - chronisch entzündliche Darmerkrankungen - Morbus Crohn
Key words
immunosuppression - inflammatory bowel disease - Crohn’s disease
Literatur
- 1 FDA Board Document.
Update on the TNF-alpha blocking agents; [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm]. 2003
MissingFormLabel
- 2 Akobeng A K, Gardener E. Oral 5-aminosalicylic
acid for maintenance of medically-induced remission in Crohn’s
Disease. Cochrane Database Syst Rev 2005 CD003715
MissingFormLabel
- 3 Akobeng A K, Zachos M. Tumor necrosis factor-alpha
antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2004 CD003574
MissingFormLabel
- 4
Caprilli R, Viscido A, Latella G.
Current management of severe ulcerative colitis.
Nat
Clin Pract Gastroenterol Hepatol.
2007;
4
92-101
MissingFormLabel
- 5
Cohen R D, Woseth D M, Thisted R A, Hanauer S B.
A
meta-analysis and overview of the literature on treatment options
for left-sided ulcerative colitis and ulcerative proctitis.
Am
J Gastroenterol.
2000;
95
1263-1276
MissingFormLabel
- 6
Colombel J F, Ferrari N. et al .
Genotypic
analysis of thiopurine S-methyltransferase in patients with Crohn’s
disease and severe myelosuppression during azathioprine therapy.
Gastroenterology.
2000;
118
1025-1030
MissingFormLabel
- 7
Colombel J F, Loftus Jr E V, Tremaine W J. et al .
The safety profile
of infliximab in patients with Crohn’s disease: the Mayo
clinic experience in 500 patients.
Gastroenterology.
2004;
126
19-31
MissingFormLabel
- 8
Cosnes J. et
al .
Impact of the increasing use of immunosuppressants
in Crohn’s disease on the need for intestinal surgery.
Gut.
2005;
54
237-241
MissingFormLabel
- 9
Dayharsh G A, Loftus Jr E V, Sandborn W J. et al .
Epstein-Barr virus-positive lymphoma
in patients with inflammatory bowel disease treated with azathioprine
or 6-mercaptopurine.
Gastroenterology.
2002;
122
72-77
MissingFormLabel
- 10
Feagan B G.
Maintenance therapy for inflammatory bowel disease.
Am
J Gastroenterol.
2003;
98
S6-S17
MissingFormLabel
- 11
Feagan B G, Rochon J, Fedorak R N. et al .
Methotrexate for the treatment of Crohn’s
disease.
N Engl J Med.
1995;
332
292-297
MissingFormLabel
- 12
Fernandez-Banares F, Bertran X. et al .
Azathioprine
is useful in maintaining long-term remission induced by intravenous
cyclosporine in steroid-refractory severe ulcerative colitis.
Am J Gastroenterol.
1996;
91
2498-2499
MissingFormLabel
- 13
Hanauer S B.
Immunogenicity of infliximab in Crohn’s disease.
N Engl J Med.
2003;
348
2155-2156
, ; author reply 2155 – 2156
MissingFormLabel
- 14
Hanauer S B, Sandborn W J, Rutgeerts P. et al .
Human anti-tumor necrosis
factor monoclonal antibody (adalimumab) in Crohn’s disease:
the CLASSIC-I trial.
Gastroenterology.
2006;
130
323-333; quiz 591
MissingFormLabel
- 15
Jarnerot G, Hertervig E. et al .
Infliximab
as rescue therapy in severe to moderately severe ulcerative colitis.
Gastroenterology.
2005;
128
1805-1811
MissingFormLabel
- 16
Kamm M A.
Chronic active disease and maintaining remission in Crohn’s
disease.
Aliment Pharmacol Ther.
2004;
20 Suppl 4
102-105
MissingFormLabel
- 17
Kandiel A E, Fraser A J, Korelitz B I, Brensinger C M, Lewis J D.
Azathioprine and 6-mercaptopurine
use for inflammatory bowel disease is associated with an increased
risk of lymphoma.
Gastroenterology.
2004;
126
19-26
MissingFormLabel
- 18
Katz S.
Update in medical therapy of ulcerative colitis: newer concepts
and therapies.
J Clin Gastroenterol.
2005;
39
557-569
MissingFormLabel
- 19
Kjeldsen J.
Treatment of ulcerative colitis with high doses of oral prednisolone.
The rate of remission, the need for surgery, and the effect of prolonging the
treatment.
Scand J Gastroenterol.
1993;
28
821-826
MissingFormLabel
- 20
Kozarek R A.
Long-term treatment of Crohn’s disease with methotrexate,
or, why’s a nice drug like you still a wannabe in the treatment
of inflammatory bowel disease?.
Am J Gastroenterol.
2000;
95
1619-1620
MissingFormLabel
- 21
Kremer J M, Alarcon G S, Lightfoot Jr R W. et al .
Methotrexate
for rheumatoid arthritis. Suggested guidelines for monitoring liver
toxicity. American College of Rheumatology.
Arthritis
Rheum.
1994;
37
316-328
MissingFormLabel
- 22
Kwon H J, Farrell R J.
The risk of
lymphoma in the treatment of inflammatory bowel disease with immunosuppressive
agents.
Crit Rev Oncol Hematol.
2005;
56
169-178
MissingFormLabel
- 23
Lemann M, Mary J Y, Colombel J F. et al .
A randomized, double-blind,
controlled withdrawal trial in Crohn’s disease patients
in long-term remission on azathioprine.
Gastroenterology.
2005;
128
1812-1818
MissingFormLabel
- 24
Lemann M, Zenjari T, Bouhnik Y. et
al .
Methotrexate in Crohn’s disease: long-term
efficacy and toxicity.
Am J Gastroenterol.
2000;
95
1730-1734
MissingFormLabel
- 25
Lewis J D.
How safe is immunomodulator therapy?.
Inflamm Bowel
Dis.
2001;
7
178-179
MissingFormLabel
- 26
Lewis J D, Bilker W B. et al .
Inflammatory
bowel disease is not associated with an increased risk of lymphoma.
Gastroenterology.
2001;
121
1080-1087
MissingFormLabel
- 27
Lichtenstein G R, Feagan B G, Cohen R D. et al .
Serious infections
and mortality in association with therapies for Crohn’s
disease: TREAT registry.
Clin Gastroenterol Hepatol.
2006;
4
621-630
MissingFormLabel
- 28
Lichtiger S, Present D H, Kornbluth A. et al .
Cyclosporine in severe ulcerative colitis
refractory to steroid therapy.
N Engl J Med.
1994;
330
1841-1845
MissingFormLabel
- 29
Orchard T, Probert C S, Keshav S.
Maintenance therapy in patients with ulcerative colitis.
Aliment
Pharmacol Ther.
2006;
24 Suppl 1
17-22
MissingFormLabel
- 30
Roenigk Jr H H, Auerbach R, Maibach H, Weinstein G, Lebwohl M.
Methotrexate in psoriasis: consensus conference.
Journal of the American Academy of Dermatology.
1998;
38
478-485
MissingFormLabel
- 31
Rutgeerts P.
Current dilemmas in the management of inflammatory bowel disease.
Eur J Surg .
2002;
Suppl
58-61
MissingFormLabel
- 32
Rutgeerts P, Diamond R H, Bala M. et al .
Scheduled maintenance treatment with infliximab
is superior to episodic treatment for the healing of mucosal ulceration
associated with Crohn’s disease.
Gastrointest
Endosc.
2006;
63
433-442; quiz 464
MissingFormLabel
- 33
Rutgeerts P, Van Assche G, Vermeire S.
Optimizing anti-TNF treatment in inflammatory bowel disease.
Gastroenterology.
2004;
126
1593-1610
MissingFormLabel
- 34
Rutgeerts P, Van Assche G, Vermeire S.
Infliximab therapy for inflammatory bowel disease--seven years
on.
Aliment Pharmacol Ther.
2006;
23
451-463
MissingFormLabel
- 35
Rutgeerts P J.
Efficacy of infliximab in Crohn’s disease – induction
and maintenance of remission.
Aliment Pharmacol Ther.
1999;
13 Suppl 4
9-15; discussion 38
MissingFormLabel
- 36
Safdi M, DeMicco M, Sninsky C. et
al .
A double-blind comparison of oral versus rectal
mesalamine versus combination therapy in the treatment of distal
ulcerative colitis.
Am J Gastroenterol.
1997;
92
1867-1871
MissingFormLabel
- 37
Sands B E, Anderson F H, Bernstein C N. et al .
Infliximab maintenance
therapy for fistulizing Crohn’s disease.
N Engl
J Med.
2004;
350
876-885
MissingFormLabel
- 38
Schroder O, Stein J.
Low dose methotrexate
in inflammatory bowel disease: current status and future directions.
Am J Gastroenterol.
2003;
98
530-537
MissingFormLabel
- 39 Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A
for induction of remission in severe ulcerative colitis. Cochrane
Database Syst Rev 2005 CD004277
MissingFormLabel
- 40
Siegel C A, Sands B E.
Practical management
of inflammatory bowel disease patients taking immunomodulators.
Aliment Pharmacol Ther.
2005;
22
1-16
MissingFormLabel
- 41
Sohi S, Cohen R D.
Management of refractory
ulcerative colitis.
Curr Treat Options Gastroenterol.
2006;
9
234-245
MissingFormLabel
- 42
Srinivasan R, Lewis J D.
Malignancies
in inflammatory bowel disease.
Curr Opin Gastroenterol.
2003;
19
366-370
MissingFormLabel
- 43 Sutherland L, Macdonald J K. Oral 5-aminosalicylic
acid for maintenance of remission in ulcerative colitis. Cochrane
Database Syst Rev 2006 CD000544
MissingFormLabel
- 44
Te H S, Schiano T D, Kuan S F. et al .
Hepatic effects of long-term
methotrexate use in the treatment of inflammatory bowel disease.
Am J Gastroenterol.
2000;
95
3150-3156
MissingFormLabel
- 45 Timmer A, McDonald J, Macdonald J. Azathioprine and 6-mercaptopurine for maintenance of remission
in ulcerative colitis. Cochrane Database Syst Rev 2007 CD000478
MissingFormLabel
- 46
Travis S P, Stange E F. et al .
European
evidence based consensus on the diagnosis and management of Crohn’s
disease.
Gut.
2006;
55 Suppl
1
i16-35
MissingFormLabel
- 47
Truelove S C, Witts L J.
Cortisone in
ulcerative colitis; final report on a therapeutic trial.
Br
Med J.
1955;
2
1041-1048
MissingFormLabel
- 48
Van Assche G, D’Haens G, Noman M. et al .
Randomized, double-blind comparison of
4 mg/kg versus 2 mg/kg intravenous
cyclosporine in severe ulcerative colitis.
Gastroenterology.
2003;
125
1025-1031
MissingFormLabel
- 49
Van Assche G, Vermeire S, Rutgeerts P.
Medical treatment of inflammatory bowel diseases.
Curr
Opin Gastroenterol.
2005;
21
443-447
MissingFormLabel
- 50
Vilien M, Dahlerup J F. et al .
Randomized
controlled azathioprine withdrawal after more than two years treatment
in Crohn’s disease: increased relapse rate the following
year.
Aliment Pharmacol Ther.
2004;
19
1147-1152
MissingFormLabel
Prof. Dr. Gerhard Rogler
Klinik für Gastroenterologie und Hepatologie, Department
für Innere Medizin, Universitäts-Spital
Zürich
Rämistr. 100
CH-8091
Zürich